Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$443.89−14.04 (-3.07%)
Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%
Amgen operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Amgen's operating income for the twelve months ending Sep 30, 2026 was $12.61B, up 45.4% year over year. For fiscal 2025 it was $9.08B, up 25.1% from the year before. Over ten years it grew 0.7% a year on average. The highest annual figure on record is $10.26B in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.08B | +25.1% |
| FY2024 | Dec 31, 2024 | $7.26B | -8.1% |
| FY2023 | Dec 31, 2023 | $7.90B | -17.4% |
| FY2022 | Dec 31, 2022 | $9.57B | +25.2% |
| FY2021 | Dec 31, 2021 | $7.64B | -16.4% |
| FY2020 | Dec 31, 2020 | $9.14B | -5.5% |
| FY2019 | Dec 31, 2019 | $9.67B | -5.7% |
| FY2018 | Dec 31, 2018 | $10.26B | +2.9% |
| FY2017 | Dec 31, 2017 | $9.97B | +1.8% |
| FY2016 | Dec 31, 2016 | $9.79B | +15.6% |
| FY2015 | Dec 31, 2015 | $8.47B | +36.8% |
| FY2014 | Dec 31, 2014 | $6.19B | +5.5% |
| FY2013 | Dec 31, 2013 | $5.87B | +5.2% |
| FY2012 | Dec 31, 2012 | $5.58B | +29.3% |
| FY2011 | Dec 31, 2011 | $4.31B | -22.2% |
| FY2010 | Dec 31, 2010 | $5.55B | +0.7% |
| FY2009 | Dec 31, 2009 | $5.51B | +5.6% |
| FY2008 | Dec 31, 2008 | $5.21B | +31.0% |
| FY2007 | Dec 31, 2007 | $3.98B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.71B | +46.9% |
| Q2 FY2026 | Jun 30, 2026 | $3.51B | +32.3% |
| Q1 FY2026 | Mar 31, 2026 | $2.67B | +126.3% |
| Q4 FY2025 | Dec 31, 2025 | $2.72B | +17.7% |
| Q3 FY2025 | Sep 30, 2025 | $2.53B | +23.4% |
| Q2 FY2025 | Jun 30, 2025 | $2.66B | +39.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.18B | +18.9% |
| Q4 FY2024 | Dec 31, 2024 | $2.31B | +81.8% |
| Q3 FY2024 | Sep 30, 2024 | $2.05B | +1.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.91B | -28.9% |
| Q1 FY2024 | Mar 31, 2024 | $991.00M | -48.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.27B | -43.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.02B | -24.0% |
| Q2 FY2023 | Jun 30, 2023 | $2.68B | +23.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.92B | -23.2% |
| Q4 FY2022 | Dec 31, 2022 | $2.23B | -3.2% |
| Q3 FY2022 | Sep 30, 2022 | $2.66B | +24.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.18B | +8.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.50B | +1.9% |
| Q4 FY2021 | Dec 31, 2021 | $2.30B | -0.8% |
| Q1 FY2021 | Mar 31, 2021 | $2.13B | -9.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.01B | -25.0% |
| Q3 FY2020 | Sep 30, 2020 | $2.45B | -0.8% |
| Q2 FY2020 | Jun 30, 2020 | $2.32B | -2.5% |
| Q1 FY2020 | Mar 31, 2020 | $2.36B | +1.4% |
| Q2 FY2019 | Jun 30, 2019 | $2.68B | -5.4% |
| Q1 FY2019 | Mar 31, 2019 | $2.47B | -9.3% |
| Q4 FY2018 | Dec 31, 2018 | $2.38B | +6.1% |
| Q3 FY2018 | Sep 30, 2018 | $2.32B | -4.8% |
| Q2 FY2018 | Jun 30, 2018 | $2.83B | +5.0% |
| Q1 FY2018 | Mar 31, 2018 | $2.73B | +5.2% |
| Q4 FY2017 | Dec 31, 2017 | $2.25B | -9.7% |
| Q3 FY2017 | Sep 30, 2017 | $2.44B | -3.5% |
| Q2 FY2017 | Jun 30, 2017 | $2.70B | +13.4% |
| Q1 FY2017 | Mar 31, 2017 | $2.59B | – |
| Q4 FY2016 | Dec 31, 2016 | $2.49B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.53B | – |
| Q2 FY2016 | Jun 30, 2016 | $2.38B | – |
See a number that looks wrong?